A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer.

To characterize programmed cell death ligand-1 (PD-L1) expression in relation to survival and gene mutation status in patients with advanced NSCLC. The study also explored the influence of tumor mutational burden (TMB) on PD-L1 expression and patient characteristics. Adult patients with histologically or cytologically documented Stage IIIB/Stage IV/recurrent/progressive NSCLC, Eastern Cooperative Oncology Group performance status 0 to 3, and >2 lines of prior systemic treatment regimens were included in this retrospective analysis. Patients were treated from 1997 to 2015 at H. Lee Moffitt Cancer Center and Research Institute, Tampa, or at 7 community centers across the United States. PD-L1 expression level was determined using the VENTANA PD-L1 (SP263) Assay. From a total of 136 patients included in the study, 23.5% had tumors with high PD-L1 expression (≥25%). There were no significant differences in patient characteristics, overall survival (OS), and progression-free survival (PFS) between patients with high PD-L1 expression (median OS: 39.5 months; median PFS: 15.8 months) vs low PD-L1 expression (<25%; median OS: 38.1 months; median PFS: 18.6 months). PD-L1 expression level correlated (P=0.05) with TMB and was consistent with The Cancer Genome Atlas data. In this retrospective analysis, survival outcomes of patients with advanced NSCLC were comparable by PD-L1 expression level.

Informations de copyright

© 2019 Schabath et al.

Déclaration de conflit d'intérêts

Dr. Gray receives research grants and personal fees from AstraZeneca; research grants from Merck, Bristol Myers Squibb, and Genentech, during the conduct of the study. She is an advisor for AstraZeneca. She also reports research grants and personal fees from AstraZeneca and Genentech; research grants from Array, Merck, Epic Sciences, Bristol Myers Squibb, Boehringer Ingelheim, Trovagene, and Novartis; personal fees from Takeda, Eli Lilly, Celgene, and Janssen, outside of the submitted work. Drs. Dalvi, Midha, Shire, Walker, and Rigas are employees of AstraZeneca and hold stock in the company. Dr Brody is now a retiree and was an employee of AstraZeneca at the time of the study. Dr Potter was an employee of AstraZeneca at the time of the study and currently an AstraZeneca stockholder. Drs. Greenawalt and Lawrence were employees of AstraZeneca at the time of the study and are currently employed with Bristol-Myers Squibb, USA, and Novartis, Switzerland, respectively. Drs Dai and Crim are employees of M2Gen. Drs Kumar and Huntsman were employees of M2Gen at the time of the study. The authors report no other conflicts of interest in this work.